BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology 2017;6:e1305531. [PMID: 28638726 DOI: 10.1080/2162402X.2017.1305531] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Ring A, Spataro M, Wicki A, Aceto N. Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. Front Cell Dev Biol 2022;10:929893. [DOI: 10.3389/fcell.2022.929893] [Reference Citation Analysis]
2 Wijesiriwardhana P, Musolf AM, Bailey-Wilson JE, Wetthasinghe TK, Dissanayake VHW. Genome-wide linkage search for cancer susceptibility loci in a cohort of non BRCA1/2 families in Sri Lanka. BMC Res Notes 2022;15:190. [PMID: 35655316 DOI: 10.1186/s13104-022-06081-5] [Reference Citation Analysis]
3 Hoppmann N, Heinig N, Distler U, Kim E, Lennerz V, Krauß Y, Schumann U, Giese A, Tenzer S, Bitar L, Schmidt MHH. Gamma Irradiation Triggers Immune Escape in Glioma-Propagating Cells. Cancers (Basel) 2022;14:2728. [PMID: 35681710 DOI: 10.3390/cancers14112728] [Reference Citation Analysis]
4 Asleh K, Negri GL, Spencer Miko SE, Colborne S, Hughes CS, Wang XQ, Gao D, Gilks CB, Chia SKL, Nielsen TO, Morin GB. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat Commun 2022;13:896. [PMID: 35173148 DOI: 10.1038/s41467-022-28524-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rajaratinam H, Mokhtar NF, Asma-abdullah N, Fuad WEM. Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives. Biomolecules 2022;12:310. [DOI: 10.3390/biom12020310] [Reference Citation Analysis]
6 Roetman JJ, Apostolova MKI, Philip M. Viral and cellular oncogenes promote immune evasion. Oncogene 2022. [PMID: 35022539 DOI: 10.1038/s41388-021-02145-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shen M, Smith HA, Wei Y, Jiang YZ, Zhao S, Wang N, Rowicki M, Tang Y, Hang X, Wu S, Wan L, Shao ZM, Kang Y. Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat Cancer 2022;3:60-74. [PMID: 35121988 DOI: 10.1038/s43018-021-00280-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Li Y, Liu X, Chen H, Xie P, Ma R, He J, Zhang H. Bioinformatics analysis for the role of CALR in human cancers. PLoS One 2021;16:e0261254. [PMID: 34910788 DOI: 10.1371/journal.pone.0261254] [Reference Citation Analysis]
9 Nelson A, Lukacs JD, Johnston B. The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead. Cancers (Basel) 2021;13:5174. [PMID: 34680322 DOI: 10.3390/cancers13205174] [Reference Citation Analysis]
10 Radosevic-Robin N, Selenica P, Zhu Y, Won HH, Berger MF, Ferrando L, Cocco E, Privat M, Ponelle-Chachuat F, Abrial C, Nabholtz JM, Penault-Llorca F, Reis-Filho JS, Scaltriti M. Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. NPJ Breast Cancer 2021;7:124. [PMID: 34535679 DOI: 10.1038/s41523-021-00334-5] [Reference Citation Analysis]
11 Bai X, Ni J, Beretov J, Graham P, Li Y. Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. Journal of the National Cancer Center 2021;1:75-87. [DOI: 10.1016/j.jncc.2021.06.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Llinàs-Arias P, Íñiguez-Muñoz S, McCann K, Voorwerk L, Orozco JIJ, Ensenyat-Mendez M, Sesé B, DiNome ML, Marzese DM. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:4139. [PMID: 34439290 DOI: 10.3390/cancers13164139] [Reference Citation Analysis]
13 Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat 2021. [PMID: 34322780 DOI: 10.1007/s10549-021-06337-x] [Reference Citation Analysis]
14 Wang S, Xie K, Liu T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol 2021;12:690112. [PMID: 34367148 DOI: 10.3389/fimmu.2021.690112] [Reference Citation Analysis]
15 Cai C, Long J, Huang Q, Han Y, Peng Y, Guo C, Liu S, Chen Y, Shen E, Long K, Wang X, Yu J, Shen H, Zeng S. M6A "Writer" Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer. Front Oncol 2021;11:615296. [PMID: 34221955 DOI: 10.3389/fonc.2021.615296] [Reference Citation Analysis]
16 Shen J, Liu T, Bei Q, Xu S. Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis. Front Oncol 2021;11:685065. [PMID: 34222009 DOI: 10.3389/fonc.2021.685065] [Reference Citation Analysis]
17 Gebremeskel S, Nelson A, Walker B, Oliphant T, Lobert L, Mahoney D, Johnston B. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J Immunother Cancer 2021;9:e002096. [PMID: 33722907 DOI: 10.1136/jitc-2020-002096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol 2021;12:636568. [PMID: 33767702 DOI: 10.3389/fimmu.2021.636568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
19 Yang S, Tang D, Zhao YC, Liu H, Luo S, Stinchcombe TE, Glass C, Su L, Shen S, Christiani DC, Wang Q, Wei Q. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. Cancer Immunol Immunother 2021;70:2819-33. [PMID: 33651148 DOI: 10.1007/s00262-021-02877-9] [Reference Citation Analysis]
20 Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, Seifert U, Dittmer U, Schuler M, Lang KS, Kufer TA, Hartmann G, Becker JC, Horn S, Ferrone S, Liu D, Van Allen EM, Schadendorf D, Griewank K, Trilling M, Paschen A. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest 2020;130:4266-81. [PMID: 32427578 DOI: 10.1172/JCI131572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
21 Lv Y, Ma X, Du Y, Feng J. Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets. Onco Targets Ther 2021;14:589-607. [PMID: 33519208 DOI: 10.2147/OTT.S293685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Alame M, Cornillot E, Cacheux V, Rigau V, Costes-Martineau V, Lacheretz-Szablewski V, Colinge J. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics 2021;11:3565-79. [PMID: 33664848 DOI: 10.7150/thno.54343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter AB, Dong E, Cao S, Wang J, Schneider BP, Sandusky GE, Liu Y, Zhang C, Lu X, Zhang X. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest 2021;131:140837. [PMID: 32990678 DOI: 10.1172/JCI140837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Pralea IE, Moldovan RC, Țigu AB, Ionescu C, Iuga CA. Mass Spectrometry-Based Omics for the Characterization of Triple-Negative Breast Cancer Bio-Signature. J Pers Med 2020;10:E277. [PMID: 33322818 DOI: 10.3390/jpm10040277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. J Natl Cancer Inst 2019;111:970-82. [PMID: 30698726 DOI: 10.1093/jnci/djy209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
26 Nelson LJ, Wright HJ, Dinh NB, Nguyen KD, Razorenova OV, Heinemann FS. Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers. Am J Pathol 2020;190:484-502. [PMID: 31843498 DOI: 10.1016/j.ajpath.2019.10.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Garrido MA, Rodriguez T, Zinchenko S, Maleno I, Ruiz-Cabello F, Concha Á, Olea N, Garrido F, Aptsiauri N. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics 2018;70:647-59. [PMID: 30145665 DOI: 10.1007/s00251-018-1074-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
28 Cheng Y, Monteiro C, Matos A, You J, Fraga A, Pereira C, Catalán V, Rodríguez A, Gómez-Ambrosi J, Frühbeck G, Ribeiro R, Hu P. Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study. Clin Epigenetics 2018;10:54. [PMID: 29692867 DOI: 10.1186/s13148-018-0490-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM. T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. Acta Neuropathol 2018;135:581-99. [PMID: 29350274 DOI: 10.1007/s00401-018-1806-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
30 Romero I, Garrido C, Algarra I, Chamorro V, Collado A, Garrido F, Garcia-Lora AM. MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy. Front Immunol 2018;9:102. [PMID: 29434605 DOI: 10.3389/fimmu.2018.00102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]